Cannabidiol in Sickle Cell Disease

Part of paid clinical trials in Manhattan, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT06930703
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cannabidiol — DRUG
    Cannabidiol (CBD) twice daily taken orally for 4-weeks
  • Placebo — DRUG
    Placebo equivalent twice daily taken orally for 4-weeks

Study Details

Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

Key Dates

Start date
Apr 3, 2025
Status verified
Apr 2025
Primary completion
Feb 1, 2027
Completion
Feb 1, 2027

Study Design

Enrollment
52 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Placebo Comparator: Placebo
    Twice daily matching placebo
  • Active Comparator: Cannabidiol 200 mg
    Twice daily 200 mg cannabidiol
  • Active Comparator: Cannabidiol 400 mg
    Twice daily 400 mg cannabidiol
  • Active Comparator: Cannabidiol 600 mg
    Twice daily 600 mg cannabidiol

Primary Outcome Measure

Tumor Necrosis Factor-alpha level [ Time Frame: at 4 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiManhattanNew York10029
Susanna Curtis, MD, PhD
[email protected]
Susanna Curtis (PRINCIPAL_INVESTIGATOR)

Find similar trials in Manhattan, NY

By condition
Sickle cell disease
By research site
Icahn School of Medicine at Mount Sinai· Manhattan, NY

Related Studies